Comparative Pharmacology
Head-to-head clinical analysis: IOPAMIDOL 250 IN PLASTIC CONTAINER versus RENORMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOPAMIDOL 250 IN PLASTIC CONTAINER versus RENORMAX.
IOPAMIDOL-250 IN PLASTIC CONTAINER vs RENORMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated radiographic contrast medium that attenuates X-rays and provides radiopacity in vascular and body cavities. It does not undergo significant pharmacological activity.
Selective beta-1 adrenergic receptor antagonist; reduces cardiac output, heart rate, and blood pressure by blocking catecholamine effects on cardiac beta-1 receptors.
250 mg iodine/mL; 1.5 mL/kg (up to 100 mL) IV bolus or infusion for CT imaging.
5 mg intravenously every 12 hours
None Documented
None Documented
Terminal elimination half-life: 2 hours (normal renal function); prolonged in renal impairment (up to 30+ hours in severe impairment), dictating contrast dosing intervals
Terminal elimination half-life: 8-10 hours in healthy adults. Prolonged to 18-24 hours in moderate renal impairment (CrCl 30-50 mL/min). Provides basis for twice-daily dosing in normal renal function.
Renal: 95% unchanged via glomerular filtration; biliary/fecal: <5%
Primarily renal (60-70% unchanged; 10-15% as glucuronide conjugate); biliary/fecal (5-10%); 80-85% total recovered in urine and feces within 72 hours.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent